ChromaDex Corp. has announced a newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside (NRH) and dihydronicotinic acid riboside (NARH).
ChromaDex Corp. has announced a newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside (NRH) and dihydronicotinic acid riboside (NARH). The new patent is part of the patent family titled “Methods of Preparing Nicotinamide Riboside and Derivatives Thereof” exclusively licensed from Queen’s University Belfast.
ChromaDex currently owns and licenses a robust portfolio of over 60 patents related to its patented NR called Niagen and other NAD+ precursors. Niagen is the sole active ingredient in ChromaDex’s flagship consumer product, Tru Niagen, which the company boasts is the most efficient and well-studied NAD+ precursor on the market. The composition claims of the newly granted patents cover the commercially viable form of NRH and NARH, which allow ChromaDex to launch future innovations.
“There is a great deal of interest in the scientific community around NRH,” said Rob Fried, CEO of ChromaDex. “Early studies have shown impressive results as a powerful NAD+ precursor. This patent covers food, dietary supplement and pharmaceutical applications.”
Preclinical research suggests that NRH is a more efficient and potent inducer of NAD+ compared to other precursors (1,2), and a recent study conducted by Mayo Clinic suggests that NRH may promote inflammatory response in macrophages, which are white blood cells that seek out and destroy microorganisms, remove dead cells, and stimulate the action of other immune system cells (3). These results indicate that NRH may help inform our understanding of the role NAD+ and NADH metabolism has on immune response.